{
    "title": "Griffithsin vs Ebola Virus",
    "inventor_name": "Ian Michelow, et al.",
    "publication_year": null,
    "device_name": "Griffithsin (mannose-binding lectin)",
    "goal": "Provide a broad-spectrum antiviral therapy that can prevent or treat Ebola virus infection and other viral diseases.",
    "problem_addressed": "High mortality and lack of effective treatments for Ebola, HIV, SARS, HCV and related viral infections.",
    "concept_summary": "Griffithsin is a protein lectin isolated from the red alga Griffithsia sp. that binds mannose residues on viral glycoprotein shells, disrupting the viral envelope and preventing entry into host cells. Recombinant versions have been produced in Nicotiana benthamiana plants and tested in mice and guinea pigs, where they conferred immunity to Ebola after rechallenge and showed activity against HIV-1, SARS-CoV and HCV. The technology leverages natural antiviral mechanisms of mannose-binding lectins and modern plant-based biomanufacturing.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Mannose-binding lectin antiviral activity",
        "Glycoprotein shell disruption via lectin pathway",
        "Recombinant protein expression in plant hosts"
    ],
    "scientific_domains": [
        "Virology",
        "Immunology",
        "Molecular Biology",
        "Pharmacology"
    ],
    "mechanisms_of_action": [
        "Binding to viral surface mannose residues",
        "Inducing structural breakdown of viral glycoprotein matrix",
        "Neutralizing virus and facilitating immune clearance"
    ],
    "materials": [
        "Red algae (Griffithsia sp.) tissue",
        "Recombinant Griffithsin protein",
        "Nicotiana benthamiana plant biomass"
    ],
    "energy_sources": [],
    "inputs": [
        "Ebola virus (or other target virus)",
        "Recombinant Griffithsin formulation",
        "Animal model (mouse, guinea pig) infection"
    ],
    "outputs": [
        "Reduced viral replication",
        "Protection against lethal Ebola challenge",
        "Broad-spectrum antiviral activity"
    ],
    "claimed_performance": "Mice given recombinant Griffithsin became immune to Ebola upon rechallenge; in-vitro and in-vivo studies show inhibition of HIV-1, SARS-CoV and HCV.",
    "experimental_evidence": "Animal studies in mice and guinea pigs demonstrated protection against Ebola and HIV-1 after administration of recombinant Griffithsin; in-vitro assays showed binding and neutralization of multiple viral glycoproteins.",
    "replication_status": null,
    "keywords": [
        "Griffithsin",
        "Mannose-binding lectin",
        "Red algae",
        "Ebola virus",
        "Antiviral protein",
        "Plant-based recombinant expression"
    ],
    "related_technologies": [
        "Other mannose-binding lectins (e.g., Scytovirin, Cyanovirin-N)",
        "Plant molecular farming",
        "Broad-spectrum antiviral therapeutics"
    ],
    "controversy_level": "low",
    "confidence_score": 0.8,
    "practicability_score": 0.6,
    "fringe_score": 0.2,
    "evidence_strength": 0.7,
    "risk_score": 0.2,
    "trl_estimate": 5,
    "source_urls": [
        "http://www.greenmedinfo.com/blog/red-algae-extract-fights-ebola-and-hiv-sars-and-hcv",
        "https://www.ncbi.nlm.nih.gov/pubmed/15613479",
        "https://www.ncbi.nlm.nih.gov/pubmed/12614152",
        "https://www.ncbi.nlm.nih.gov/pubmed/10881895",
        "https://www.ncbi.nlm.nih.gov/pubmed/17952574"
    ],
    "organizations": [
        "National Cancer Institute (Frederick, MD)",
        "Harvard University",
        "University of Leuven",
        "University of Maryland"
    ],
    "applications": [
        "Therapeutic antiviral treatment for Ebola and other viral infections",
        "Potential vaccine adjuvant or prophylactic supplement"
    ],
    "limitations": [
        "Manufacturing relies on recombinant plant expression systems",
        "No published human clinical trial data",
        "Stability and delivery formulation not fully defined"
    ],
    "open_questions": [
        "What is the efficacy and safety profile of Griffithsin in humans?",
        "What dosing regimen provides optimal protection?",
        "Can large-scale plant production meet regulatory standards?"
    ],
    "red_flags": [],
    "evidence_quotes": [
        "Mice given the recombinant mannose-binding lectins were rechallenged with the Ebola virus, they were found to be immune to the Ebola virus.",
        "Recombinant Griffithsin was tested on mice and guinea pigs infected with HIV-1, with successful antiviral results.",
        "The protein extract was isolated by researchers from the National Cancer Institute... the protein contains 95 amino acids, and was found to bind to HIV-1 viral shells.",
        "Harvard researchers tested a recombinant version of Griffithsin against Ebola. Once again, they found the mannose-binding lectins were able to not only breakdown the viral shells of the Ebola.",
        "In all the studies, the Griffithsin was found to be safe and tolerated."
    ]
}